These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

174 related articles for article (PubMed ID: 19601814)

  • 41. Current approved options for treating patients with multiple sclerosis.
    Rizvi SA; Agius MA
    Neurology; 2004 Dec; 63(12 Suppl 6):S8-14. PubMed ID: 15623672
    [TBL] [Abstract][Full Text] [Related]  

  • 42. New treatment strategies in multiple sclerosis.
    Jones JL; Coles AJ
    Exp Neurol; 2010 Sep; 225(1):34-9. PubMed ID: 20547155
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Multiple sclerosis: current and future treatment options.
    Rizvi S
    Endocr Metab Immune Disord Drug Targets; 2007 Dec; 7(4):292-9. PubMed ID: 18220950
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Exploring potential mechanisms of action of natalizumab in secondary progressive multiple sclerosis.
    Sellebjerg F; Cadavid D; Steiner D; Villar LM; Reynolds R; Mikol D
    Ther Adv Neurol Disord; 2016 Jan; 9(1):31-43. PubMed ID: 26788129
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Mitoxantrone for multiple sclerosis.
    Martinelli Boneschi F; Rovaris M; Capra R; Comi G
    Cochrane Database Syst Rev; 2005 Oct; (4):CD002127. PubMed ID: 16235298
    [TBL] [Abstract][Full Text] [Related]  

  • 46. The Swiss Multiple Sclerosis Cohort-Study (SMSC): A Prospective Swiss Wide Investigation of Key Phases in Disease Evolution and New Treatment Options.
    Disanto G; Benkert P; Lorscheider J; Mueller S; Vehoff J; Zecca C; Ramseier S; Achtnichts L; Findling O; Nedeltchev K; Radue EW; Sprenger T; Stippich C; Derfuss T; Louvion JF; Kamm CP; Mattle HP; Lotter C; Du Pasquier R; Schluep M; Pot C; Lalive PH; Yaldizli Ö; Gobbi C; Kappos L; Kuhle J;
    PLoS One; 2016; 11(3):e0152347. PubMed ID: 27032105
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Established and novel disease-modifying treatments in multiple sclerosis.
    Cross AH; Naismith RT
    J Intern Med; 2014 Apr; 275(4):350-63. PubMed ID: 24444048
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Statin treatment in multiple sclerosis: a systematic review and meta-analysis.
    Pihl-Jensen G; Tsakiri A; Frederiksen JL
    CNS Drugs; 2015 Apr; 29(4):277-91. PubMed ID: 25795002
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Employment and absenteeism in working-age persons with multiple sclerosis.
    Salter A; Thomas N; Tyry T; Cutter G; Marrie RA
    J Med Econ; 2017 May; 20(5):493-502. PubMed ID: 28035846
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Multiple sclerosis: clinical presentation, diagnosis and treatment.
    Brod SA; Lindsey JW; Wolinsky JS
    Am Fam Physician; 1996 Sep; 54(4):1301-6, 1309-11. PubMed ID: 8816574
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Treatment with disease-modifying drugs for people with a first clinical attack suggestive of multiple sclerosis.
    Filippini G; Del Giovane C; Clerico M; Beiki O; Mattoscio M; Piazza F; Fredrikson S; Tramacere I; Scalfari A; Salanti G
    Cochrane Database Syst Rev; 2017 Apr; 4(4):CD012200. PubMed ID: 28440858
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Composite Marker of Cognitive Dysfunction and Brain Atrophy is Highly Accurate in Discriminating Between Relapsing-Remitting and Secondary Progressive Multiple Sclerosis.
    Kizlaitienė R; Kaubrys G; Giedraitienė N; Ramanauskas N; Dementavičienė J
    Med Sci Monit; 2017 Feb; 23():588-597. PubMed ID: 28145395
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Intravenous immunoglobulin in primary and secondary chronic progressive multiple sclerosis: a randomized placebo controlled multicentre study.
    Pöhlau D; Przuntek H; Sailer M; Bethke F; Koehler J; König N; Heesen C; Späth P; Andresen I
    Mult Scler; 2007 Nov; 13(9):1107-17. PubMed ID: 17623736
    [TBL] [Abstract][Full Text] [Related]  

  • 54. [New therapeutic strategies for remyelination in multiple sclerosis].
    Kremer D; Hartung HP; Stangel M; Küry P
    Nervenarzt; 2015 Aug; 86(8):934-46. PubMed ID: 26122637
    [TBL] [Abstract][Full Text] [Related]  

  • 55. B cell depletion in the treatment of multiple sclerosis.
    Myhr KM; Torkildsen Ø; Lossius A; Bø L; Holmøy T
    Expert Opin Biol Ther; 2019 Mar; 19(3):261-271. PubMed ID: 30632834
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Genetic differences between primary progressive and relapsing-remitting multiple sclerosis: The impact of immune-related genes variability.
    Kiselev I; Bashinskaya V; Baulina N; Kozin M; Popova E; Boyko A; Favorova O; Kulakova O
    Mult Scler Relat Disord; 2019 Apr; 29():130-136. PubMed ID: 30711878
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Serum soluble adhesion molecules in multiple sclerosis: raised sVCAM-1, sICAM-1 and sE-selectin in primary progressive disease.
    McDonnell GV; McMillan SA; Douglas JP; Droogan AG; Hawkins SA
    J Neurol; 1999 Feb; 246(2):87-92. PubMed ID: 10195402
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Review of mitoxantrone in the treatment of multiple sclerosis.
    Jeffery DR; Herndon R
    Neurology; 2004 Dec; 63(12 Suppl 6):S19-24. PubMed ID: 15623665
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Natural history of multiple sclerosis: a unifying concept.
    Confavreux C; Vukusic S
    Brain; 2006 Mar; 129(Pt 3):606-16. PubMed ID: 16415308
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Adhesion molecules in multiple sclerosis: relation to subtypes of disease and methylprednisolone therapy.
    Elovaara I; Ukkonen M; Leppäkynnäs M; Lehtimäki T; Luomala M; Peltola J; Dastidar P
    Arch Neurol; 2000 Apr; 57(4):546-51. PubMed ID: 10768630
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.